89bio, Inc.
NASDAQ:ETNB
9.29 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.273 | 0.24 | 0.079 | 0.06 | 0.017 | 0.006 |
| Gross Profit
| -0.273 | -0.24 | -0.079 | -0.06 | -0.017 | -0.006 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 122.23 | 80.796 | 70.33 | 36.199 | 21.346 | 13.681 |
| General & Administrative Expenses
| 28.974 | 21.453 | 19.413 | 13.156 | 5.294 | 1.481 |
| Selling & Marketing Expenses
| -0.273 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.974 | 21.453 | 19.413 | 13.156 | 5.294 | 1.481 |
| Other Expenses
| 0 | 0.242 | -0.526 | -0.203 | -30.562 | -0.986 |
| Operating Expenses
| 144.962 | 102.249 | 89.743 | 49.355 | 26.64 | 15.162 |
| Operating Income
| -151.204 | 102.249 | -89.743 | -49.355 | -26.64 | -15.162 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 12.882 | -204.256 | -0.526 | -0.203 | -30.562 | -0.986 |
| Income Before Tax
| -138.322 | -102.007 | -90.269 | -49.558 | -57.202 | -16.148 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 3.867 | 0.019 | -0.147 | -0.059 | 0.218 | 0.028 |
| Net Income
| -142.189 | -102.026 | -90.122 | -49.499 | -57.42 | -16.176 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2 | -2.93 | -4.48 | -3.08 | -24.49 | -3.53 |
| EPS Diluted
| -2 | -2.93 | -4.48 | -3.08 | -24.49 | -3.53 |
| EBITDA
| -151.154 | -102.249 | -89.743 | -49.355 | -26.64 | -15.156 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |